...
首页> 外文期刊>Clinical and experimental pharmacology & physiology >Possible anti-atherogenic effect of kolaviron (a Garcinia kola seed extract) in hypercholesterolaemic rats.
【24h】

Possible anti-atherogenic effect of kolaviron (a Garcinia kola seed extract) in hypercholesterolaemic rats.

机译:Kolaviron(藤黄可乐种子提取物)对高胆固醇血症大鼠的抗动脉粥样硬化作用。

获取原文
获取原文并翻译 | 示例
           

摘要

SUMMARY 1. The hypolipidaemic effect of kolaviron, a mixture of Garcinia biflavonoid 1 (GB1), Garcinia biflavonoid 2 (GB2) and kolaflavanone, used in the treatment of various ailments in southern Nigeria, was investigated in rats. The ability of Questran (Bristol-Myers Squibb, Hounslow, UK), a hypolipidaemic therapeutic drug, to attenuate hypercholesterolaemia in rats was also examined. 2. In order to assess the hypolipidaemic effect of this extract in experimental animals, thiobarbituric acid-reactive substances (TBARS), cholesterol, phospholipid, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol and triglyceride levels were determined in the plasma and liver. 3. Cholesterol administered orally to rats at a dose of 30 mg/0.3 mL five times a week for 8 consecutive weeks resulted in a significant increase (P < 0.001) in the relative weight of the heart of hypercholesterolaemic animals compared with control. However, cotreatment with kolaviron and Questran ameliorated the cholesterol-induced enlargement of the heart. Kolaviron (100 and 200 mg/kg) elicited 88.5 and 87.4% reductions, respectively, in plasma cholesterol levels of pretreated animals compared with the cholesterol-fed group. In addition, kolaviron produced a significant decrease (P < 0.05) in post-mitochondrial fraction (PMF) cholesterol levels in treated animals compared with untreated hypercholesterolaemic animals. Similarly, Questran significantly decreased (P < 0.05) the cholesterol-induced increase in plasma cholesterol levels compared with untreated hypercholesterolaemic animals. In addition, (100 and 200 mg/kg) significantly (P < 0.05) decreased plasma LDL-C levels by over 70% in treated animals compared with untreated hypercholesterolaemic animals. Similarly, kolaviron significantly decreased (P < 0.05) PMF LDL-C levels by over 60% in treated animals compared with untreated hypercholesterolaemic animals. 4. The significantly (P < 0.05) higher values of plasma and PMF triglycerides obtained in cholesterol-fedanimals compared with control animals were unaltered following cotreatment with kolaviron and Questran. In the present study, there was a significant decrease (P < 0.05) in plasma formation of malondialdehyde in kolaviron- and Questran-treated animals compared with untreated hypercholesterolaemic animals. 5. The results of the present study demonstrate that kolaviron exerts a hypocholesterolaemic effect and reduces the relative weight of the heart in cholesterol-fed animals. This reduction and the favourable lipid profile indicate a possible anti-atherogenic property of the extract.
机译:概述1.研究了在尼日利亚南部用于治疗各种疾病的藤黄双黄酮1(GB1),藤黄双黄酮2(GB2)和可乐黄酮的混合物降糖素的降血脂作用。还检查了降血脂治疗药物Questran(Bristol-Myers Squibb,Hounslow,UK)减轻大鼠高胆固醇血症的能力。 2.为了评估该提取物对实验动物的降血脂作用,对硫代巴比妥酸反应性物质(TBARS),胆固醇,磷脂,低密度脂蛋白胆固醇(LDL-C),高密度脂蛋白胆固醇和甘油三酸酯水平被确定在血浆和肝脏。 3.连续五周,每周五次以30 mg / 0.3 mL的剂量口服给予大鼠胆固醇,与对照组相比,高胆固醇血症动物心脏的相对体重显着增加(P <0.001)。然而,与kolaviron和Questran的共同治疗改善了胆固醇诱导的心脏肿大。与胆固醇喂养组相比,Kolaviron(100和200 mg / kg)分别使预处理动物的血浆胆固醇水平降低了88.5%和87.4%。此外,与未经治疗的高胆固醇血症动物相比,经治疗的动物中的克拉维龙的线粒体后分数(PMF)胆固醇水平显着降低(P <0.05)。同样,与未经治疗的高胆固醇血症动物相比,Questran显着降低(P <0.05)胆固醇诱导的血浆胆固醇水平的升高。此外,与未治疗的高胆固醇血症动物相比,治疗的动物中(100和200 mg / kg)的血浆LDL-C水平显着降低(P <0.05)70%以上。同样,与未经治疗的高胆固醇血症动物相比,经治疗的动物中的克拉法铁显着降低(P <0.05)PMF LDL-C水平超过60%。 4.与对照动物相比,在胆固醇雌性动物中获得的血浆和PMF甘油三酯的显着(P <0.05)值较高,但与克拉维铁和Questran共同处理后未改变。在本研究中,与未经治疗的高胆固醇血症动物相比,在经克拉维铁和Questran治疗的动物中,丙二醛的血浆形成显着降低(P <0.05)。 5.本研究的结果表明,在以胆固醇喂养的动物中,克拉瓦龙具有降胆固醇的功效,并能降低心脏的相对体重。这种减少和有利的脂质特征表明提取物可能具有抗动脉粥样硬化特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号